查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1593758

即時診斷市場評估：按產品、處方、最終用戶和地區劃分的機會和預測（2017-2031）

Point-of-Care Diagnostics Market Assessment, By Product, By Prescription, By End-user, By Region, Opportunities and Forecast, 2017-2031F
出版日期: | 出版商: Market Xcel - Markets and Data | 英文 234 Pages | 商品交期: 3-5個工作天內

價格

全球即時診斷市場規模預計將從 2023 年的 472.1 億美元增長到 2031 年的 867.4 億美元，預測期內複合年增長率為 7.90%。

推動即時診斷市場的因素包括傳染病爆發的增加、對人工智慧等技術的投資增加、對分散式醫療解決方案的需求不斷增長以及企業投資的增加。除此之外，家庭醫療保健的改善趨勢也改善了病患體驗並降低了醫療成本。

世界各地的護理點診斷包括快速現場測試，可以立即做出臨床決策。這些測試很重要，因為它們可以準確及時地報告，改善患者的治療結果，並減少對集中實驗室設施的需求。在患者護理時提供快速、可靠的診斷的強大能力使其在任何醫療保健環境中都處於有價值的類別，並將開始使世界各地的醫療保健服務變得更加高效和方便。

為了在先進的現場護理市場中建立強大的地位，公司正在透過研發投資來加強其診斷部門。此外，我們還獲得了資金來發展我們的能力並加速診斷解決方案的創新。整體而言，此類策略措施正在提高現場診斷的品質和效率，推動市場成長，並穩步增加對更快、更準確測試的需求。

本報告調查了全球即時診斷市場，提供了市場定義和概述、市場規模趨勢和預測、各個細分市場/地區/主要國家的詳細分析、行業結構以及影響因素的市場成長分析、研究、競爭格局和主要公司簡介。

目錄

第1章專案範圍與定義

第2章研究方法

第 3 章執行摘要

第 4 章 COVID-19 對全球護理點診斷市場的影響

第五章客戶回饋

  • 產品與市場訊息
  • 品牌識別模式
  • 做出購買決定時考慮的因素
  • 隱私和監管考慮因素

第6章全球即時診斷市場展望

  • 市場規模分析與預測
  • 市佔率分析/預測
    • 按產品
    • 按處方
    • 按最終用戶
    • 按地區
    • 按公司劃分的市佔率分析
  • 市場地圖分析

第7章北美即時診斷市場展望

  • 市場規模分析與預測
  • 市佔率分析/預測
  • 國家市場評估
    • 美國
    • 加拿大
    • 墨西哥

第 8 章歐洲即時診斷市場展望

  • 德國
  • 法國
  • 義大利
  • 英國
  • 俄羅斯
  • 荷蘭
  • 西班牙
  • 土耳其
  • 波蘭

第 9 章亞太地區護理診斷市場前景

  • 印度
  • 中國
  • 日本
  • 澳大利亞
  • 越南
  • 韓國
  • 印尼
  • 菲律賓

第10章南美洲即時診斷市場展望

  • 巴西
  • 阿根廷

第 11 章中東與非洲的護理點診斷市場前景

  • 沙烏地阿拉伯
  • 阿聯酋
  • 南非

第12章供需分析

第13章價值鏈分析

第 14 章波特五力分析

第15章PESTLE分析

第16章價格分析

第 17 章市場動態

  • 市場驅動因素
  • 市場課題

第18章市場趨勢與發展

第 19 章法律與監管架構/創新

  • 監理機關的核准

第 20 章個案研究

第21章競爭態勢

  • 前 5 名市場領導者的競爭矩陣
  • 前 5 名的公司的 SWOT 分析
  • 前10名企業狀況
    • Abbott Laboratories
    • F. Hoffmann-La Roche Ltd
    • Cepheid Inc.
    • Becton Dickinson and Company
    • BioMerieux SA
    • Sekisui Diagnostics, LLC
    • Qiagen N.V.
    • Cipla Limited
    • QuidelOrtho Corporation
    • Nova Biomedical Corporation

第 22 章策略建議

第23章關於我們公司/免責聲明

Product Code: MX12270

Global point-of-care diagnostics market is projected to witness a CAGR of 7.90% during the forecast period 2024-2031, growing from USD 47.21 billion in 2023 to USD 86.74 billion in 2031.

Factors driving the point-of-care diagnostics market include the rising prevalence of infectious diseases, increased investment in technology that includes artificial intelligence, growing demand for decentralized healthcare solutions, and increased corporate investments. Apart from this, improvement in the trend towards home care improves the patient's experience and lowers the costs of healthcare as well.

Global point-of-care (POC) diagnostics consists of rapid, on-site tests that enable immediate clinical decision-making. These tests are significant as they allow accurate and timely reporting, improving patient care results and reducing the need for centralized lab facilities. Its high ability to deliver fast, reliable diagnostics at the point of patient care positions it in a valuable category in every healthcare setting, initiating a more efficient, accessible healthcare delivery worldwide.

Companies are strengthening their diagnostics segment through R&D investment to gain a solid stand in the advanced point-of-care diagnostics market. Moreover, they obtain funds to develop their capabilities and speed up innovation in diagnostic solutions. Overall, these strategic initiatives enhance the quality and efficiency of POC diagnostics, fueling market growth and steadily increasing demand for faster, more accurate testing. For instance, in July 2024, NOWDiagnostics, Inc. (NOWDx) closed a USD 22.5 million Series B funding aimed at fast-tracking rapid at-home diagnostic tests. NOWDxwill utilize the funding for the launch of innovative diagnostics, and home-based tests and expand the portfolio of tests. NOWDx has a promising clinical research pipeline of around 30 diagnostic tests, and the company is willing to utilize the funding for the approval and commercialization of these tests.

Similarly, in August 2024, Lumos Diagnostics Holdings Limited (Lumos), a rapid POC diagnostic solutions manufacturer, extended its partnership with the Burnet Institute to conduct a clinical trial of a new POC test for monitoring liver health. This kind of development suggests that the market is expanding and increasing demand to innovate liver function monitoring and pave the way for future home-based tests.

Technological Advancements of Point-of-Care Diagnostics

Technological advancement is driving the growth of point-of-care diagnostics as a viable means to ease healthcare burdens. These devices are user-friendly and inexpensive, with rapid turnaround times; thus, they suit patients with financial constraints, social stigma, and mobility issues. Miniaturized biochip devices can detect diseases rapidly using simple samples such as blood or saliva. Integrating AI and microfluidic technologies improves diagnostic precision and efficiency, making it possible for POC devices to detect biomarkers in a wide range of conditions, from infectious diseases to oncology and many more. For instance, in June 2023, Sysmex Corporation launched its first point-of-care testing system for Europe, designed to diagnose antimicrobial susceptibility in 30 minutes rapidly. Using microfluidic technology, the system rapidly detects bacteria, analyzes the effectiveness of antimicrobial drugs using urine samples, and is likely to alter conventional approaches toward the diagnosis of infectious diseases and deal with the imperative urgency of speeding up the detection of UTI infections.

Growing Preference for Home Care Driving Market Growth

The growing preference for healthcare services at home is a key driver for growth in the point-of-care diagnostics segment. Patients are now looking for convenient, cost-effective, and more customized care delivery. There has been a rising demand for diagnostic tests that can be performed outside traditional clinical settings. POC diagnostics allow people to track their health conditions from the comfort of their homes. This reduces the number of hospital visits and decreases healthcare costs. The availability, accessibility, and usability of home-based diagnosis solutions are attractive factors contributing to increased usage and driving the market in the health sector. For instance, in March 2023, Cue Health Inc. launched a portfolio of home-based diagnostic test kits that offer company test-to-treat services to help people with easy health management from their homes. The marketed kits include heart health test kits, sexual health test kits, women's health test kits, metabolic health test kits, and wellness test kits. These kits are enabled with Cue Care, allowing a simple and private collection of samples for the CLIA-certified independent laboratory analysis. The results are efficiently provided in the Cue Health App, coupled with relevant health information.

Favorable Funding Scenario to Fuel Market Growth

The COVID-19 pandemic has significantly transformed the funding landscape of point-of-care diagnostics. Health disparities caused during the pandemic highlight the need for fast, accurate, and accessible testing. In response, funding for R&D has surged to develop advanced and more point-of-care diagnostic tests. That additional funding helped drive faster the development of new POC diagnostics solutions that could rapidly and effectively diagnose and treat health conditions. The capital inflow has also expanded testing capabilities beyond COVID-19 to a broader set of conditions and applications. For this reason, the market is likely to experience tremendous growth, with ongoing investment remaining in a core position to drive diagnostic innovations in terms of improved access to healthcare for populations.

For instance, in March 2024, BioMerieux SA invested USD 10.76 million (NOK 115 million) to develop a small-scale immunoassay POC analyzer with SpinChip Diagnostics ASA. This advanced platform delivers diagnostic performance from a single blood droplet within minutes and has scalability across the POC market. The first product is a high-sensitivity cardiac troponin I test, which will be a monumental step in the method of emergency triaging and treatment of acute heart attacks.

Infectious Disease Testing Products Dominating Point-of-Care Diagnostics Market

Infectious disease testing products hold the largest share of the POC diagnostics market. They create an utmost need to provide rapid, on-site diagnosis for conditions such as COVID-19, HIV, influenza, and tuberculosis. These tests can be done immediately; thus, results can speed up the decisions about treatment, and infectious diseases will not spread faster as they are being diagnosed promptly. The portability and ease with which they may be used in even clinical settings, as well as remote or resource-limited areas, ensure their effectiveness. The growing epidemics of infectious diseases coupled with the technological advancements in POC testing devices further gave strength to these tools for controlling outbreaks and managing public health challenges effectively.

In August 2023, QuidelOrtho Corporation received De Novo FDA approval for its Sofia 2 SARS Antigen+ FIA. The prescription test is well-suited to point-of-care settings, supporting companies' efforts to expand their product offerings for infectious disease testing. This approval reflects the ongoing trend of companies looking at upgrading diagnostic offerings by securing regulatory approvals and launching more advanced tests to respond to growing demand.

North America Dominates Point-of-Care Diagnostics Market Share

North America holds the largest share in the point-of-care diagnostics market due to robust healthcare infrastructure and is largely supported by the government, which leads to the encouragement of innovation and significant adoption of more advanced diagnostic technologies. The presence of prominent market players creates competition, and this, in turn, leads to a continued development in product offerings. For instance, in July 2023, Vital Biosciences Inc., a Canada-based company, launched its first point-of-care testing platform, VitalOne, a compact device roughly the size of a desktop computer, at the Annual Meeting of the American Association of Clinical Chemistry. It will revolutionize diagnostics, as the system can provide more than 50 lab-grade results within 20 minutes. Moreover, regional companies are streamlining efforts, helping drive its leadership. In July 2024, Babson Diagnostics, Inc. introduced its new BetterWay blood testing service at Austin retail pharmacies. This BetterWay enables patients to be tested at retail pharmacies. This makes access easier for consumers. This will encourage more people to seek such diagnostic services, further fueling the demand in the market.

Future Market Scenario (2024-2031F)

This market is expected to hold several growth opportunities in the coming years due to an increasing prevalence of infectious disease, advancement in point-of-care diagnostic technologies, growing advancements in home care diagnostics, and an increase in investments toward research and development activities. In addition, AI-integrated testing holds great promise in the future toward both accuracy and usability, and researchers are working to make the innovation even better. For example, in August 2024, a team at the University of California, Los Angeles (UCLA) managed to design an AI-based test similar to home-based COVID-19 tests that would detect Lyme disease accurately in under 20 minutes.

Key Players Landscape and Outlook

The global point-of-care diagnostics market is relatively competitive. Companies are enforcing their position through strategic collaborations, inventions of new and accurate testing methods, acquisition of necessary regulatory clearances, and diversification of their product portfolios to improve accessibility and fulfill rising healthcare demands.

In August 2024, F. Hoffmann-La Roche Ltd expanded its partnership with Glytec, LLC, to enhance hospital diabetes management. Through this collaboration, Glytec's software will be integrated with Roche's Cobas pulse point-of-care blood glucose system, which is looking to enhance safety and quality of care along with cost-effectiveness for patients. Its lab-quality results minimize the retesting rate, and Cobas pulse is suitable for a wide range of patient groups, including neonates and intensive care patients.

In March 2024, QuidelOrtho Corporation received Health Canada approval for its Triage PLGF test for laboratory use nationwide. The fluorescence immunoassay measuring placental growth factor (PLGF) in maternal plasma is used with the Triage MeterPro Instrument to detect angiogenic imbalance caused by poor placental blood flow, which may lead to pregnancy complications, including pre-eclampsia. Such testing can diagnose preterm pre-eclampsia and predict short-term risks for delivery.

Table of Contents

1. Project Scope and Definitions

2. Research Methodology

3. Executive Summary

4. Impact of COVID-19 on Global Point-of-Care Diagnostics Market

5. Voice of Customer

  • 5.1. Product and Market Intelligence
  • 5.2. Mode of Brand Awareness
  • 5.3. Factors Considered in Purchase Decisions
    • 5.3.1. Features and Other Value-Added Service
    • 5.3.2. Infrastructure Compatibility
    • 5.3.3. Efficiency of Solutions
    • 5.3.4. After-Sales Support
  • 5.4. Consideration of Privacy and Regulations

6. Global Point-of-Care Diagnostics Market Outlook, 2017-2031F

  • 6.1. Market Size Analysis & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share Analysis & Forecast
    • 6.2.1. By Product
      • 6.2.1.1. Glucose Monitoring
        • 6.2.1.1.1. Strips
        • 6.2.1.1.2. Meters
        • 6.2.1.1.3. Lancets
      • 6.2.1.2. Cardiometabolic Testing Products
        • 6.2.1.2.1. Cardiac Marker Testing Products
          • 6.2.1.2.1.1. High Sensitive Troponin-I (hsTnl)
          • 6.2.1.2.1.2. Brain natriuretic peptide (BNP)
          • 6.2.1.2.1.3. D-dimer
          • 6.2.1.2.1.4. Creatine Kinase-MB (CK-MB)
          • 6.2.1.2.1.5. Myoglobin
          • 6.2.1.2.1.6. Others
        • 6.2.1.2.2. Blood Gas/Electrolytes Testing Products
        • 6.2.1.2.3. HbA1C Testing Products
      • 6.2.1.3. Infectious Disease Testing Products
        • 6.2.1.3.1. Sexually Transmitted Disease (STD) Testing Products
        • 6.2.1.3.2. Healthcare-associated Infection (HAI) Testing Products
        • 6.2.1.3.3. Respiratory Infection Testing Products
        • 6.2.1.3.4. Tropical Disease Testing Products
        • 6.2.1.3.5. Others
      • 6.2.1.4. Coagulation Testing Products
        • 6.2.1.4.1. Prothrombin Time Testing Products
        • 6.2.1.4.2. Activated Clotting Time/Activated Partial Thromboplastin Clotting Time (ACT/APTT) Testing Products
      • 6.2.1.5. Pregnancy and Fertility Testing Products
        • 6.2.1.5.1. Pregnancy Testing Products
        • 6.2.1.5.2. Fertility Testing Products
      • 6.2.1.6. Tumor/cancer Marker Testing Products
      • 6.2.1.7. Cholesterol Testing Products
      • 6.2.1.8. Hematology Testing Products
      • 6.2.1.9. Drug-of-abuse (DoA) Testing Products
      • 6.2.1.10. Fecal Occult Testing Products
      • 6.2.1.11. Urinalysis Testing Products
      • 6.2.1.12. Others
    • 6.2.2. By Prescription
      • 6.2.2.1. OTC Testing
      • 6.2.2.2. Prescription-based Testing
    • 6.2.3. By End-user
      • 6.2.3.1. Hospitals
      • 6.2.3.2. Diagnostic Centers
      • 6.2.3.3. Research Laboratories
      • 6.2.3.4. Home-care Settings
      • 6.2.3.5. Others
    • 6.2.4. By Region
      • 6.2.4.1. North America
      • 6.2.4.2. Europe
      • 6.2.4.3. Asia-Pacific
      • 6.2.4.4. South America
      • 6.2.4.5. Middle East and Africa
    • 6.2.5. By Company Market Share Analysis (Top 5 Companies and Others - By Value, 2023)
  • 6.3. Market Map Analysis, 2023
    • 6.3.1. By Product
    • 6.3.2. By Prescription
    • 6.3.3. By End-user
    • 6.3.4. By Region

7. North America Point-of-Care Diagnostics Market Outlook, 2017-2031F*

  • 7.1. Market Size Analysis & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share Analysis & Forecast
    • 7.2.1. By Product
      • 7.2.1.1. Glucose Monitoring
        • 7.2.1.1.1. Strips
        • 7.2.1.1.2. Meters
        • 7.2.1.1.3. Lancets
      • 7.2.1.2. Cardiometabolic Testing Products
        • 7.2.1.2.1. Cardiac Marker Testing Products
          • 7.2.1.2.1.1. High Sensitive Troponin-I (hsTnl)
          • 7.2.1.2.1.2. Brain natriuretic peptide (BNP)
          • 7.2.1.2.1.3. D-dimer
          • 7.2.1.2.1.4. Creatine Kinase-MB (CK-MB)
          • 7.2.1.2.1.5. Myoglobin
          • 7.2.1.2.1.6. Others
        • 7.2.1.2.2. Blood Gas/Electrolytes Testing Products
        • 7.2.1.2.3. HbA1C Testing Products
      • 7.2.1.3. Infectious Disease Testing Products
        • 7.2.1.3.1. Sexually Transmitted Disease (STD) Testing Products
        • 7.2.1.3.2. Healthcare-associated Infection (HAI) Testing Products
        • 7.2.1.3.3. Respiratory Infection Testing Products
        • 7.2.1.3.4. Tropical Disease Testing Products
        • 7.2.1.3.5. Others
      • 7.2.1.4. Coagulation Testing Products
        • 7.2.1.4.1. Prothrombin Time Testing Products
        • 7.2.1.4.2. Activated Clotting Time/Activated Partial Thromboplastin Clotting Time (ACT/APTT) Testing Products
      • 7.2.1.5. Pregnancy and Fertility Testing Products
        • 7.2.1.5.1. Pregnancy Testing Products
        • 7.2.1.5.2. Fertility Testing Products
      • 7.2.1.6. Tumor/cancer Marker Testing Products
      • 7.2.1.7. Cholesterol Testing Products
      • 7.2.1.8. Hematology Testing Products
      • 7.2.1.9. Drug-of-abuse (DoA) Testing Products
      • 7.2.1.10. Fecal Occult Testing Products
      • 7.2.1.11. Urinalysis Testing Products
      • 7.2.1.12. Others
    • 7.2.2. By Prescription
      • 7.2.2.1. OTC Testing
      • 7.2.2.2. Prescription-based Testing
    • 7.2.3. By End-user
      • 7.2.3.1. Hospitals
      • 7.2.3.2. Diagnostic Centers
      • 7.2.3.3. Research Laboratories
      • 7.2.3.4. Home-care Settings
      • 7.2.3.5. Others
    • 7.2.4. By Country Share
      • 7.2.4.1. United States
      • 7.2.4.2. Canada
      • 7.2.4.3. Mexico
  • 7.3. Country Market Assessment
    • 7.3.1. United States Point-of-Care Diagnostics Market Outlook, 2017-2031F*
      • 7.3.1.1. Market Size Analysis & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share Analysis & Forecast
        • 7.3.1.2.1. By Product
          • 7.3.1.2.1.1. Glucose Monitoring
          • 7.3.1.2.1.1.1. Strips
          • 7.3.1.2.1.1.2. Meters
          • 7.3.1.2.1.1.3. Lancets
          • 7.3.1.2.1.2. Cardiometabolic Testing Products
          • 7.3.1.2.1.2.1. Cardiac Marker Testing Products
          • 7.3.1.2.1.2.1.1. High Sensitive Troponin-I (hsTnl)
          • 7.3.1.2.1.2.1.2. Brain natriuretic peptide (BNP)
          • 7.3.1.2.1.2.1.3. D-dimer
          • 7.3.1.2.1.2.1.4. Creatine Kinase-MB (CK-MB)
          • 7.3.1.2.1.2.1.5. Myoglobin
          • 7.3.1.2.1.2.1.6. Others
          • 7.3.1.2.1.2.2. Blood Gas/Electrolytes Testing Products
          • 7.3.1.2.1.2.3. HbA1C Testing Products
          • 7.3.1.2.1.3. Infectious Disease Testing Products
          • 7.3.1.2.1.3.1. Sexually Transmitted Disease (STD) Testing Products
          • 7.3.1.2.1.3.2. Healthcare-associated Infection (HAI) Testing Products
          • 7.3.1.2.1.3.3. Respiratory Infection Testing Products
          • 7.3.1.2.1.3.4. Tropical Disease Testing Products
          • 7.3.1.2.1.3.5. Others
          • 7.3.1.2.1.4. Coagulation Testing Products
          • 7.3.1.2.1.4.1. Prothrombin Time Testing Products
          • 7.3.1.2.1.4.2. Activated Clotting Time/Activated Partial Thromboplastin Clotting Time (ACT/APTT) Testing Products
          • 7.3.1.2.1.5. Pregnancy and Fertility Testing Products
          • 7.3.1.2.1.5.1. Pregnancy Testing Products
          • 7.3.1.2.1.5.2. Fertility Testing Products
          • 7.3.1.2.1.6. Tumor/cancer Marker Testing Products
          • 7.3.1.2.1.7. Cholesterol Testing Products
          • 7.3.1.2.1.8. Hematology Testing Products
          • 7.3.1.2.1.9. Drug-of-abuse (DoA) Testing Products
          • 7.3.1.2.1.10. Fecal Occult Testing Products
          • 7.3.1.2.1.11. Urinalysis Testing Products
          • 7.3.1.2.1.12. Others
        • 7.3.1.2.2. By Prescription
          • 7.3.1.2.2.1. OTC Testing
          • 7.3.1.2.2.2. Prescription-based Testing
        • 7.3.1.2.3. By End-user
          • 7.3.1.2.3.1. Hospitals
          • 7.3.1.2.3.2. Diagnostic Centers
          • 7.3.1.2.3.3. Research Laboratories
          • 7.3.1.2.3.4. Home-care Settings
          • 7.3.1.2.3.5. Others
    • 7.3.2. Canada
    • 7.3.3. Mexico

All segments will be provided for all regions and countries covered

8. Europe Point-of-Care Diagnostics Market Outlook, 2017-2031F

  • 8.1. Germany
  • 8.2. France
  • 8.3. Italy
  • 8.4. United Kingdom
  • 8.5. Russia
  • 8.6. Netherlands
  • 8.7. Spain
  • 8.8. Turkey
  • 8.9. Poland

9. Asia-Pacific Point-of-Care Diagnostics Market Outlook, 2017-2031F

  • 9.1. India
  • 9.2. China
  • 9.3. Japan
  • 9.4. Australia
  • 9.5. Vietnam
  • 9.6. South Korea
  • 9.7. Indonesia
  • 9.8. Philippines

10. South America Point-of-Care Diagnostics Market Outlook, 2017-2031F

  • 10.1. Brazil
  • 10.2. Argentina

11. Middle East and Africa Point-of-Care Diagnostics Market Outlook, 2017-2031F

  • 11.1. Saudi Arabia
  • 11.2. UAE
  • 11.3. South Africa

12. Demand Supply Analysis

13. Value Chain Analysis

14. Porter's Five Forces Analysis

15. PESTLE Analysis

16. Pricing Analysis

17. Market Dynamics

  • 17.1. Market Drivers
  • 17.2. Market Challenges

18. Market Trends and Developments

19. Regulatory Framework and Innovation

  • 19.1. Regulatory Approvals

20. Case Studies

21. Competitive Landscape

  • 21.1. Competition Matrix of Top 5 Market Leaders
  • 21.2. SWOT Analysis for Top 5 Players
  • 21.3. Key Players Landscape for Top 10 Market Players
    • 21.3.1. Abbott Laboratories
      • 21.3.1.1. Company Details
      • 21.3.1.2. Key Management Personnel
      • 21.3.1.3. Products and Services
      • 21.3.1.4. Financials (As Reported)
      • 21.3.1.5. Key Market Focus and Geographical Presence
      • 21.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisition
    • 21.3.2. F. Hoffmann-La Roche Ltd
    • 21.3.3. Cepheid Inc.
    • 21.3.4. Becton Dickinson and Company
    • 21.3.5. BioMerieux SA
    • 21.3.6. Sekisui Diagnostics, LLC
    • 21.3.7. Qiagen N.V.
    • 21.3.8. Cipla Limited
    • 21.3.9. QuidelOrtho Corporation
    • 21.3.10. Nova Biomedical Corporation

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

22. Strategic Recommendations

23. About Us and Disclaimer

List of Tables

  • Table 1. Pricing Analysis of Products from Key Players
  • Table 2. Competition Matrix of Top 5 Market Leaders
  • Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
  • Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

  • Figure 1. Global Point-of-Care Diagnostics Market, By Value, In USD Billion, 2017-2031F
  • Figure 2. Global Point-of-Care Diagnostics Market Share (%), By Product, 2017-2031F
  • Figure 3. Global Point-of-Care Diagnostics Market Share (%), By Prescription, 2017-2031F
  • Figure 4. Global Point-of-Care Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 5. Global Point-of-Care Diagnostics Market Share (%), By Region, 2017-2031F
  • Figure 6. North America Point-of-Care Diagnostics Market, By Value, In USD Billion, 2017-2031F
  • Figure 7. North America Point-of-Care Diagnostics Market Share (%), By Product, 2017-2031F
  • Figure 8. North America Point-of-Care Diagnostics Market Share (%), By Prescription, 2017-2031F
  • Figure 9. North America Point-of-Care Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 10. North America Point-of-Care Diagnostics Market Share (%), By Country, 2017-2031F
  • Figure 11. United States Point-of-Care Diagnostics Market, By Value, In USD Billion, 2017-2031F
  • Figure 12. United States Point-of-Care Diagnostics Market Share (%), By Product, 2017-2031F
  • Figure 13. United States Point-of-Care Diagnostics Market Share (%), By Prescription, 2017-2031F
  • Figure 14. United States Point-of-Care Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 15. Canada Point-of-Care Diagnostics Market, By Value, In USD Billion, 2017-2031F
  • Figure 16. Canada Point-of-Care Diagnostics Market Share (%), By Product, 2017-2031F
  • Figure 17. Canada Point-of-Care Diagnostics Market Share (%), By Prescription, 2017-2031F
  • Figure 18. Canada Point-of-Care Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 19. Mexico Point-of-Care Diagnostics Market, By Value, In USD Billion, 2017-2031F
  • Figure 20. Mexico Point-of-Care Diagnostics Market Share (%), By Product, 2017-2031F
  • Figure 21. Mexico Point-of-Care Diagnostics Market Share (%), By Prescription, 2017-2031F
  • Figure 22. Mexico Point-of-Care Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 23. Europe Point-of-Care Diagnostics Market, By Value, In USD Billion, 2017-2031F
  • Figure 24. Europe Point-of-Care Diagnostics Market Share (%), By Product, 2017-2031F
  • Figure 25. Europe Point-of-Care Diagnostics Market Share (%), By Prescription, 2017-2031F
  • Figure 26. Europe Point-of-Care Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 27. Europe Point-of-Care Diagnostics Market Share (%), By Country, 2017-2031F
  • Figure 28. Germany Point-of-Care Diagnostics Market, By Value, In USD Billion, 2017-2031F
  • Figure 29. Germany Point-of-Care Diagnostics Market Share (%), By Product, 2017-2031F
  • Figure 30. Germany Point-of-Care Diagnostics Market Share (%), By Prescription, 2017-2031F
  • Figure 31. Germany Point-of-Care Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 32. France Point-of-Care Diagnostics Market, By Value, In USD Billion, 2017-2031F
  • Figure 33. France Point-of-Care Diagnostics Market Share (%), By Product, 2017-2031F
  • Figure 34. France Point-of-Care Diagnostics Market Share (%), By Prescription, 2017-2031F
  • Figure 35. France Point-of-Care Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 36. Italy Point-of-Care Diagnostics Market, By Value, In USD Billion, 2017-2031F
  • Figure 37. Italy Point-of-Care Diagnostics Market Share (%), By Product, 2017-2031F
  • Figure 38. Italy Point-of-Care Diagnostics Market Share (%), By Prescription, 2017-2031F
  • Figure 39. Italy Point-of-Care Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 40. United Kingdom Point-of-Care Diagnostics Market, By Value, In USD Billion, 2017-2031F
  • Figure 41. United Kingdom Point-of-Care Diagnostics Market Share (%), By Product, 2017-2031F
  • Figure 42. United Kingdom Point-of-Care Diagnostics Market Share (%), By Prescription, 2017-2031F
  • Figure 43. United Kingdom Point-of-Care Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 44. Russia Point-of-Care Diagnostics Market, By Value, In USD Billion, 2017-2031F
  • Figure 45. Russia Point-of-Care Diagnostics Market Share (%), By Product, 2017-2031F
  • Figure 46. Russia Point-of-Care Diagnostics Market Share (%), By Prescription, 2017-2031F
  • Figure 47. Russia Point-of-Care Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 48. Netherlands Point-of-Care Diagnostics Market, By Value, In USD Billion, 2017-2031F
  • Figure 49. Netherlands Point-of-Care Diagnostics Market Share (%), By Product, 2017-2031F
  • Figure 50. Netherlands Point-of-Care Diagnostics Market Share (%), By Prescription, 2017-2031F
  • Figure 51. Netherlands Point-of-Care Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 52. Spain Point-of-Care Diagnostics Market, By Value, In USD Billion, 2017-2031F
  • Figure 53. Spain Point-of-Care Diagnostics Market Share (%), By Product, 2017-2031F
  • Figure 54. Spain Point-of-Care Diagnostics Market Share (%), By Prescription, 2017-2031F
  • Figure 55. Spain Point-of-Care Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 56. Turkey Point-of-Care Diagnostics Market, By Value, In USD Billion, 2017-2031F
  • Figure 57. Turkey Point-of-Care Diagnostics Market Share (%), By Product, 2017-2031F
  • Figure 58. Turkey Point-of-Care Diagnostics Market Share (%), By Prescription, 2017-2031F
  • Figure 59. Turkey Point-of-Care Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 60. Poland Point-of-Care Diagnostics Market, By Value, In USD Billion, 2017-2031F
  • Figure 61. Poland Point-of-Care Diagnostics Market Share (%), By Product, 2017-2031F
  • Figure 62. Poland Point-of-Care Diagnostics Market Share (%), By Prescription, 2017-2031F
  • Figure 63. Poland Point-of-Care Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 64. South America Point-of-Care Diagnostics Market, By Value, In USD Billion, 2017-2031F
  • Figure 65. South America Point-of-Care Diagnostics Market Share (%), By Product, 2017-2031F
  • Figure 66. South America Point-of-Care Diagnostics Market Share (%), By Prescription, 2017-2031F
  • Figure 67. South America Point-of-Care Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 68. South America Point-of-Care Diagnostics Market Share (%), By Country, 2017-2031F
  • Figure 69. Brazil Point-of-Care Diagnostics Market, By Value, In USD Billion, 2017-2031F
  • Figure 70. Brazil Point-of-Care Diagnostics Market Share (%), By Product, 2017-2031F
  • Figure 71. Brazil Point-of-Care Diagnostics Market Share (%), By Prescription, 2017-2031F
  • Figure 72. Brazil Point-of-Care Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 73. Argentina Point-of-Care Diagnostics Market, By Value, In USD Billion, 2017-2031F
  • Figure 74. Argentina Point-of-Care Diagnostics Market Share (%), By Product, 2017-2031F
  • Figure 75. Argentina Point-of-Care Diagnostics Market Share (%), By Prescription, 2017-2031F
  • Figure 76. Argentina Point-of-Care Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 77. Asia-Pacific Point-of-Care Diagnostics Market, By Value, In USD Billion, 2017-2031F
  • Figure 78. Asia-Pacific Point-of-Care Diagnostics Market Share (%), By Product, 2017-2031F
  • Figure 79. Asia-Pacific Point-of-Care Diagnostics Market Share (%), By Prescription, 2017-2031F
  • Figure 80. Asia-Pacific Point-of-Care Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 81. Asia-Pacific Point-of-Care Diagnostics Market Share (%), By Country, 2017-2031F
  • Figure 82. India Point-of-Care Diagnostics Market, By Value, In USD Billion, 2017-2031F
  • Figure 83. India Point-of-Care Diagnostics Market Share (%), By Product, 2017-2031F
  • Figure 84. India Point-of-Care Diagnostics Market Share (%), By Prescription, 2017-2031F
  • Figure 85. India Point-of-Care Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 86. China Point-of-Care Diagnostics Market, By Value, In USD Billion, 2017-2031F
  • Figure 87. China Point-of-Care Diagnostics Market Share (%), By Product, 2017-2031F
  • Figure 88. China Point-of-Care Diagnostics Market Share (%), By Prescription, 2017-2031F
  • Figure 89. China Point-of-Care Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 90. Japan Point-of-Care Diagnostics Market, By Value, In USD Billion, 2017-2031F
  • Figure 91. Japan Point-of-Care Diagnostics Market Share (%), By Product, 2017-2031F
  • Figure 92. Japan Point-of-Care Diagnostics Market Share (%), By Prescription, 2017-2031F
  • Figure 93. Japan Point-of-Care Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 94. Australia Point-of-Care Diagnostics Market, By Value, In USD Billion, 2017-2031F
  • Figure 95. Australia Point-of-Care Diagnostics Market Share (%), By Product, 2017-2031F
  • Figure 96. Australia Point-of-Care Diagnostics Market Share (%), By Prescription, 2017-2031F
  • Figure 97. Australia Point-of-Care Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 98. Vietnam Point-of-Care Diagnostics Market, By Value, In USD Billion, 2017-2031F
  • Figure 99. Vietnam Point-of-Care Diagnostics Market Share (%), By Product, 2017-2031F
  • Figure 100. Vietnam Point-of-Care Diagnostics Market Share (%), By Prescription, 2017-2031F
  • Figure 101. Vietnam Point-of-Care Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 102. South Korea Point-of-Care Diagnostics Market, By Value, In USD Billion, 2017-2031F
  • Figure 103. South Korea Point-of-Care Diagnostics Market Share (%), By Product, 2017-2031F
  • Figure 104. South Korea Point-of-Care Diagnostics Market Share (%), By Prescription, 2017-2031F
  • Figure 105. South Korea Point-of-Care Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 106. Indonesia Point-of-Care Diagnostics Market, By Value, In USD Billion, 2017-2031F
  • Figure 107. Indonesia Point-of-Care Diagnostics Market Share (%), By Product, 2017-2031F
  • Figure 108. Indonesia Point-of-Care Diagnostics Market Share (%), By Prescription, 2017-2031F
  • Figure 109. Indonesia Point-of-Care Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 110. Philippines Point-of-Care Diagnostics Market, By Value, In USD Billion, 2017-2031F
  • Figure 111. Philippines Point-of-Care Diagnostics Market Share (%), By Product, 2017-2031F
  • Figure 112. Philippines Point-of-Care Diagnostics Market Share (%), By Prescription, 2017-2031F
  • Figure 113. Philippines Point-of-Care Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 114. Middle East & Africa Point-of-Care Diagnostics Market, By Value, In USD Billion, 2017-2031F
  • Figure 115. Middle East & Africa Point-of-Care Diagnostics Market Share (%), By Product, 2017-2031F
  • Figure 116. Middle East & Africa Point-of-Care Diagnostics Market Share (%), By Prescription, 2017-2031F
  • Figure 117. Middle East & Africa Point-of-Care Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 118. Middle East & Africa Point-of-Care Diagnostics Market Share (%), By Country, 2017-2031F
  • Figure 119. Saudi Arabia Point-of-Care Diagnostics Market, By Value, In USD Billion, 2017-2031F
  • Figure 120. Saudi Arabia Point-of-Care Diagnostics Market Share (%), By Product, 2017-2031F
  • Figure 121. Saudi Arabia Point-of-Care Diagnostics Market Share (%), By Prescription, 2017-2031F
  • Figure 122. Saudi Arabia Point-of-Care Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 123. UAE Point-of-Care Diagnostics Market, By Value, In USD Billion, 2017-2031F
  • Figure 124. UAE Point-of-Care Diagnostics Market Share (%), By Product, 2017-2031F
  • Figure 125. UAE Point-of-Care Diagnostics Market Share (%), By Prescription, 2017-2031F
  • Figure 126. UAE Point-of-Care Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 127. South Africa Point-of-Care Diagnostics Market, By Value, In USD Billion, 2017-2031F
  • Figure 128. South Africa Point-of-Care Diagnostics Market Share (%), By Product, 2017-2031F
  • Figure 129. South Africa Point-of-Care Diagnostics Market Share (%), By Prescription, 2017-2031F
  • Figure 130. South Africa Point-of-Care Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 131. By Product Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 132. By Prescription Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 133. By End-user Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 134. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023